Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$30.50 USD
-0.04 (-0.13%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $30.51 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XENE 30.50 -0.04(-0.13%)
Will XENE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XENE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XENE
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
XENE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue?
Other News for XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XENE ...
Xenon Pharmaceuticals Inc (XENE) Announces Equity Inducement Grants | XENE stock news
BlackRock, Inc. Expands Stake in Xenon Pharmaceuticals Inc.
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
COMMODORE CAPITAL LP Acquires 1,175,000 Shares in Cidara Therapeutics Inc